~~UNITED STATES~~0001018735false--12-31Q32024205491.75P2Y7M24D00010187352024-01-012024-09-300001018735nymox:DirectorsMember2023-01-012023-09-300001018735nymox:DirectorsMember2023-07-012023-09-300001018735nymox:DirectorsMember2024-01-012024-09-300001018735nymox:DirectorsMember2024-07-012024-09-300001018735nymox:JamesGRobinsonMember2024-09-012024-09-180001018735nymox:JamesGRobinsonMember2024-08-012024-08-230001018735nymox:JamesGRobinsonMember2024-07-012024-07-310001018735nymox:JamesGRobinsonMember2024-07-012024-07-020001018735nymox:JamesGRobinsonMember2024-06-012024-06-070001018735nymox:JamesGRobinsonMember2024-05-012024-05-030001018735nymox:JamesGRobinsonMember2024-04-012024-04-190001018735nymox:JamesGRobinsonMember2024-02-012024-02-2800010187352024-01-012024-01-1500010187352023-10-012023-10-3100010187352023-10-012023-10-1100010187352023-10-012023-10-2400010187352023-08-012023-08-280001018735nymox:JamesGRobinsonMember2024-01-012024-09-3000010187352023-04-012023-04-1700010187352023-01-012023-12-310001018735nymox:StockOptionsMember2024-01-012024-09-300001018735nymox:StockOptionsMember2024-09-300001018735nymox:PrivatePlacementsMember2024-01-012024-09-300001018735nymox:PrivatePlacementsMember2022-01-012022-03-310001018735nymox:PrivatePlacementsMember2023-10-012023-12-310001018735nymox:PrivatePlacementsMember2023-07-012023-09-300001018735nymox:PrivatePlacementsMember2022-03-310001018735nymox:EquityOptionMember2023-01-012023-09-300001018735nymox:EquityOptionMember2023-07-012023-09-300001018735nymox:EquityOptionMember2024-07-012024-09-300001018735nymox:AggregateMember2023-01-012023-09-300001018735nymox:AggregateMember2024-07-012024-09-300001018735nymox:AggregateMember2023-07-012023-09-300001018735nymox:AggregateMember2024-01-012024-09-300001018735nymox:TwoThousandTwentyThreeMember2023-01-012023-09-300001018735nymox:TwoThousandTwentyThreeMember2024-07-012024-09-300001018735nymox:TwoThousandTwentyThreeMember2023-07-012023-09-300001018735nymox:TwoThousandTwentyMember2023-01-012023-09-300001018735nymox:TwoThousandTwentyTwoMember2023-01-012023-09-300001018735nymox:TwoThousandTwentyTwoMember2023-07-012023-09-300001018735nymox:TwoThousandTwentyTwoMember2024-07-012024-09-300001018735nymox:TwoThousandTwentyMember2024-07-012024-09-300001018735nymox:TwoThousandTwentyMember2023-07-012023-09-300001018735nymox:TwoThousandFifteenMember2023-01-012023-09-300001018735nymox:TwoThousandFifteenMember2023-07-012023-09-300001018735nymox:TwoThousandFifteenMember2024-01-012024-09-300001018735nymox:TwoThousandFifteenMember2024-07-012024-09-300001018735nymox:EquityOptionMember2024-09-300001018735nymox:EquityOptionMember2024-01-012024-09-300001018735nymox:EquityOptionMember2023-12-310001018735ifrs-full:RetainedEarningsMember2024-09-300001018735nymox:AdditionalPaidinCapitalsMember2024-09-300001018735nymox:ShareCapitalPayableMember2024-09-300001018735nymox:CommonStockMember2024-09-300001018735ifrs-full:RetainedEarningsMember2024-01-012024-09-300001018735nymox:AdditionalPaidinCapitalsMember2024-01-012024-09-300001018735nymox:ShareCapitalPayableMember2024-01-012024-09-300001018735nymox:CommonStockMember2024-01-012024-09-300001018735ifrs-full:RetainedEarningsMember2023-12-310001018735nymox:AdditionalPaidinCapitalsMember2023-12-310001018735nymox:ShareCapitalPayableMember2023-12-310001018735nymox:CommonStockMember2023-12-310001018735ifrs-full:RetainedEarningsMember2023-09-300001018735nymox:AdditionalPaidinCapitalsMember2023-09-300001018735nymox:ShareCapitalPayableMember2023-09-300001018735nymox:CommonStockMember2023-09-300001018735ifrs-full:RetainedEarningsMember2023-01-012023-09-300001018735nymox:AdditionalPaidinCapitalsMember2023-01-012023-09-300001018735nymox:ShareCapitalPayableMember2023-01-012023-09-300001018735nymox:CommonStockMember2023-01-012023-09-300001018735ifrs-full:RetainedEarningsMember2022-12-310001018735nymox:AdditionalPaidinCapitalsMember2022-12-310001018735nymox:ShareCapitalPayableMember2022-12-310001018735nymox:CommonStockMember2022-12-3100010187352023-09-3000010187352022-12-3100010187352023-12-3100010187352024-09-3000010187352023-01-012023-09-3000010187352023-07-012023-09-3000010187352024-07-012024-09-30iso4217:USDxbrli:sharesiso4217:USDxbrli:sharesxbrli:pure

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

~~FORM~~Report ~~6-K~~of Foreign Issuer

~~REPORT~~Pursuant OFto ~~FOREIGN~~Rule ~~PRIVATE ISSUER PURSUANT TO RULE~~ 13a-16 ORor 15d-16 OF

~~THE~~under ~~SECURITIES~~the ~~EXCHANGE~~Securities ~~ACT~~Exchange OFAct of 1934

For the ~~Month~~period ofended ~~December~~September 30, 2024

Commission File Number: 001-12033

~~Nymox~~NYMOX ~~Pharmaceutical~~PHARMACEUTICAL ~~Corporation (Translation of registrant’s name into English)~~CORPORATION

~~Bay~~Indicate &by ~~Deveaux~~check ~~Streets,~~mark ~~Nassau,~~whether ~~The~~the ~~Bahamas~~ registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40‑F.

Form 20-F ☒ Form 40-F ☐

~~Listing~~Indicate onby ~~Over~~check mark if the ~~Counter~~registrant QBis ~~Venture~~submitting ~~Market~~Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(l): ☐

OnIndicate ~~December~~by ~~17,~~check ~~2024,~~mark ~~Nymox~~if ~~Pharmaceutical Corporation (~~the ~~“Company”)~~registrant ~~issued a press release announcing that the Company’s Common Stock has resumed trading under the symbol NYMXF on the Over the Counter QB (OTCQB®) Venture Market. This press release~~ is ~~furnished~~submitting ~~as Exhibit 99.1 to this report on~~ Form 6-K ~~and~~in ~~shall~~paper ~~not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934,~~ as ~~amended,~~permitted orby ~~otherwise~~Regulation ~~subject~~S-T toRule ~~the~~101(b)(7): ~~liabilities of that section.~~☐

EXHIBIT INDEX

Exhibits

99.1		Quarterly Report for the Quarter ended September 30, 2024
99.2		CEO Certifications

Exhibit No.		Description
99.1		Press Release of Nymox Pharmaceutical Corporation, dated December 17, 2024

~~SIGNATURE~~ SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, ~~hereunto~~thereunto duly authorized.

~~Date~~NYMOX PHARMACEUTICAL CORPORATION (Registrant) By: ~~December~~/s/ 17Paul Averback, ~~2024~~MD Paul Averback, MD President and Chief Executive Officer

~~NYMOX PHARMACEUTICAL CORPORATION By~~Date: ~~/s/~~January ~~Paul~~02, ~~Averback Name: Paul Averback Title: President and Chief Executive Officer~~2025

Filing Compare · NYMOX PHARMACEUTICAL CORP